{
    "Trade/Device Name(s)": [
        "Gold Standard Diagnostics Borrelia burgdorferi IgM ELISA Test Kit"
    ],
    "Submitter Information": "Gold Standard Diagnostics",
    "510(k) Number": "K200023",
    "Predicate Device Reference 510(k) Number(s)": [
        "K894293"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LSR"
    ],
    "Summary Letter Date": "December 27, 2019",
    "Summary Letter Received Date": "January 6, 2020",
    "Submission Date": "December 27, 2019",
    "Regulation Number(s)": [
        "21 CFR 866.3830"
    ],
    "Regulation Name(s)": [
        "Treponema Pallidum Treponemal Test Reagents"
    ],
    "Analyte Class(es)": [
        "microbiology",
        "immunology",
        "serology"
    ],
    "Analyte(s)": [
        "IgM antibodies to Borrelia burgdorferi sensu stricto"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Microplate reader (450 nm)"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme-linked immunosorbent assay (ELISA)",
        "Antigen-antibody complex detection"
    ],
    "Methodologies": [
        "ELISA",
        "Qualitative presumptive serological testing"
    ],
    "Submission Type(s)": [
        "Kit",
        "Assay",
        "Reagent",
        "Control",
        "Calibrator",
        "Consumable"
    ],
    "Document Summary": "FDA 510(k) summary for Gold Standard Diagnostics Borrelia burgdorferi IgM ELISA Test Kit for qualitative detection of IgM antibodies in human serum",
    "Indications for Use Summary": "Qualitative presumptive (first step) test for detection of IgM antibodies to Borrelia burgdorferi sensu stricto in human serum from symptomatic patients or those suspected of infection; positive/equivocal results require supplemental Western blot testing",
    "fda_folder": "Microbiology"
}